Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.

@article{Wong2012UndetectableHD,
  title={Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.},
  author={Grace Lai-Hung Wong and Vincent Wai-Sun Wong and H L-Y Chan and Pete C H Tse and Jason K.F. Wong and Angel M-L Chim and Karen K-L Yiu and Shirley H-T Chu},
  journal={Alimentary pharmacology & therapeutics},
  year={2012},
  volume={35 11},
  pages={1326-35}
}
BACKGROUND On-treatment monitoring of serum hepatitis B virus (HBV) DNA to guide treatment strategy for patients on entecavir has received little attention. AIM To investigate the predictive value of on-treatment HBV DNA levels for responses to entecavir. METHODS This was a retrospective cohort study among nucleos(t)ide analogue-naïve HBV-infected patients on entecavir with a minimum follow-up of 2 years. Maintained virological suppression was defined as undetectable HBV DNA (<20 IU/mL… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…